Mast Therapeutics, Inc. (MSTX)

[UpstateChris]

Everyone keeps mentioning Icahn. Perhaps I missed something in the time I was not following this. Icahn have purchased 2 blocks of ANX stock, both in the $1.80 or so range (that was PRE R/S, so $45 or so post R/S prices). One block was in his fund, the other personal. If I recall correctly (I am not looking any of this up for the purpose of this post...) both blocks were in the $4M neighborhood. After the R/S he sold the entire block from his fund and a significant portion from his personal holdings.

Did he re-purchase at some point? Did I miss some PR on that?

This is the last I read:

Carl Icahn Paring Down in Biotech, Sort Of (ANX, BIIB, ENZN, GENZ)
August 16, 2010 · Filed Under Financial, analyst calls

Adventrx Pharmaceuticals, Inc. (AMEX: ANX) no longer has to answer to Carl Icahn. The 13-F filings from Icahn Enterprise hit today and the roughly 4.3 million shares held as of March 31 is not listed in the June 30, 2010 portfolio holdings.

Icahn’s holdings of 3.2+ million shares of Biogen idec Inc. (NASDAQ: BIIB), 704,214 shares of Enzon Pharmaceuticals Inc. (NASDAQ: ENZN) and 2.62 million shares of Genzyme Corp. (NASDAQ: GENZ) appear to be the same as before.

Adventrx Pharmaceuticals’ stock is trading up 1.6% at $1.87 versus a 52-week trading range of $1.50 to $13.00. This trading range is of course on a post-split adjustment basis after its 1-for-25 reverse stock split went into effect in April. It seems that Mr. Icahn is no fan of reverse splits either.

JON C. OGG